Summary
Pfizer Inc. (PFE) announced on February 11, 2020, its intention to redeem in full its outstanding 4.20% Notes due 2047. This redemption involves a principal amount of $1.065 billion and is scheduled to occur on March 17, 2020. The redemption will be executed at a "make-whole" price, as defined by the indenture governing the notes. This action suggests Pfizer is likely taking advantage of favorable market conditions or has a strategic financial maneuver planned, potentially involving refinancing debt at a lower cost or reallocating capital. Investors holding these specific notes should be aware of the redemption date and the "make-whole" price mechanism. The company's decision to redeem these notes indicates proactive debt management. While this is a positive sign of financial health and strategic planning, it's important for bondholders to understand the implications for their investment, including the final payout and cessation of interest accrual post-redemption.
Key Highlights
- 1Pfizer Inc. (PFE) is redeeming its 4.20% Notes due 2047 in full.
- 2The aggregate principal amount outstanding of the notes to be redeemed is $1,065,000,000.
- 3The redemption is scheduled to take place on March 17, 2020.
- 4The notes will be redeemed at a "make-whole" price as specified in the indenture.
- 5Interest on the notes will cease to accrue on and after the redemption date, assuming no default by Pfizer.
- 6The Bank of New York Mellon is acting as the paying agent for the redemption.